Featuring perspectives from Dr Yelena Y Janjigian, including the following topics:

• Introduction (0:00)
• Case: A man in his early 60s with a history of Barrett's esophagus presents with HER2-positive metastatic esophageal adenocarcinoma and a PD-L1 combined positive score (CPS) of 3 — Jennifer Yannucci, MD (10:20)
• Case: A man in his early 60s with multiregimen-recurrent HER2-positive gastroesophageal junction (GEJ) adenocarcinoma (claudin 18.2-positive, PD-L1 CPS 0) — Neil Morganstein, MD (14:53)
• Case: A woman in her early 80s with dementia and newly diagnosed mismatch repair-deficient, PD-L1-positive metastatic GEJ adenocarcinoma — Brian P Mulherin, MD (25:55)
• Case: A man in his mid 60s with localized HER2-negative GEJ cancer (PD-L1 CPS 2, claudin 18.2-positive) and residual disease after receiving neoadjuvant chemoradiation therapy and undergoing surgery — Stephen "Fred" Divers, MD (32:18)
• Case: A man in his early 80s with metastatic recurrence of esophageal adenocarcinoma and a PD-L1 total proportion score of 75% 2 years after resection of localized disease — Susmitha Apuri, MD (40:28)
• Case: A man in his mid 70s with claudin 18.2-positive metastatic esophageal adenocarcinoma who develops progressive toxicities with FOLFOX and zolbetuximab — Sean Warsch, MD (52:54)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics:

• Prostate Cancer (0:00)
• Urothelial Bladder Cancer (29:18)

CME information and select publications

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics:

• Introduction: Tail on the Curve? (0:00)
• First-Line Chemoimmunotherapy (10:45)
• Maintenance Lurbinectedin (28:42)
• Second-Line Treatment, Tarlatamab (45:35)
• Ongoing Research (53:20)

CME information and select publications